- Trials with a EudraCT protocol (95)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (19)
95 result(s) found for: interferon gamma.
Displaying page 1 of 5.
EudraCT Number: 2011-001943-60 | Sponsor Protocol Number: SJF0001 | Start Date*: 2011-06-20 | ||||||||||||||||
Sponsor Name:Lars Jørgen Østergaard | ||||||||||||||||||
Full Title: Cellular immunity in adult Hepatitis B-vaccinated serologic non-responders | ||||||||||||||||||
Medical condition: Healthy individuals | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000029-31 | Sponsor Protocol Number: GIPF-007 | Start Date*: 2005-01-28 |
Sponsor Name:InterMune | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Stu... | ||
Medical condition: Idiopathic Pulmonary Fibrosis (IPF) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002541-37 | Sponsor Protocol Number: 116777 | Start Date*: 2012-08-14 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase II, open label, mono-centric study to evaluate the kinetics of mRNA expression after two doses of GSK Biologicals’ candidate tuberculosis (TB) vaccine GSK 692342 in healthy BCG-primed, HIV-... | ||
Medical condition: Healthy volunteers (Prevention of tuberculosis [TB] disease in children, adolescents and adults) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000349-42 | Sponsor Protocol Number: DurIRVac-1 | Start Date*: 2021-03-26 |
Sponsor Name:Sahlgrenska Academy, University of Gothenburg | ||
Full Title: Evaluation of the Durability of Immune Responses to SARS-CoV-2 Using Novel Rapid Spike Interferon-Gamma Release and Activation-Induced Marker Assays and Anti-Spike IgG Following COVID-19 Vaccination | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022467-36 | Sponsor Protocol Number: IFN_BOSZT_01 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Freistaat Bayern | |||||||||||||
Full Title: A phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapy | |||||||||||||
Medical condition: steroid-refractory bronchiolitis obliterans | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001881-14 | Sponsor Protocol Number: GIFT/1 | Start Date*: 2013-03-01 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: A phase II clinical trial to evaluate the safety and efficacy of interferon gamma in elevating frataxin levels in Friedreich ataxia patients | |||||||||||||
Medical condition: Friedreich's Ataxia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000753-22 | Sponsor Protocol Number: TV2/003/06 | Start Date*: 2006-05-04 |
Sponsor Name:Oxford MioMedica UK Ltd. | ||
Full Title: A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer. | ||
Medical condition: Advanced or Metastatic Renal Cell Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-003204-13 | Sponsor Protocol Number: 74527 | Start Date*: 2021-11-15 |
Sponsor Name:Radboudumc | ||
Full Title: Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia | ||
Medical condition: Candidemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014600-66 | Sponsor Protocol Number: IFN-gamma 001 | Start Date*: 2010-08-10 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University Medical Center Nijmegen | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A multicentre, prospective, randomized open-label pilot study to assess the feasibility and preliminary efficacy of interferon gamma in combination with Anidulafungin for the treatment of candidemia | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Candida bloodstream infections/ candidemia | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-001181-38 | Sponsor Protocol Number: AuspiCiOus | Start Date*: 2021-07-29 |
Sponsor Name:Academic Medical Center | ||
Full Title: Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study | ||
Medical condition: Gastroesophageal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001963-10 | Sponsor Protocol Number: 2020-CHITS-003 | Start Date*: 2020-05-12 |
Sponsor Name:Centre Hospitalier Intercommunal de Toulon La Seyne-sur-mer | ||
Full Title: Interleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation: Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib | ||
Medical condition: Covid-19 disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004953-26 | Sponsor Protocol Number: BHS-TC13 | Start Date*: 2016-03-11 |
Sponsor Name:Ghent University Hospital | ||
Full Title: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor. | ||
Medical condition: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004974-16 | Sponsor Protocol Number: IL1ra03 | Start Date*: 2018-11-08 | ||||||||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | ||||||||||||||||||
Full Title: DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED CLINICAL DOSE-RANGING STUDY TREATING MODERATE-SEVERE TRAUMATIC BRAIN INJURY PATIENTS WITH RECOMBINANT HUMAN INTERLEUKIN 1 RECEPTOR ANTAGONIST. | ||||||||||||||||||
Medical condition: We wish to study the drug Kineret in patients suffering from moderate-to-severe traumatic brain injury | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003261-18 | Sponsor Protocol Number: VITAL | Start Date*: 2019-11-22 |
Sponsor Name: | ||
Full Title: The effects of allergen immunotherapy on anti-viral immunity in patients with allergic asthma | ||
Medical condition: Allergic asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003114-10 | Sponsor Protocol Number: NI-0501-09 | Start Date*: 2018-09-06 | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AG | |||||||||||||
Full Title: An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life... | |||||||||||||
Medical condition: Primary Hemophagocytic Lymphohistiocytosis (pHLH) | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IT (Completed) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005753-23 | Sponsor Protocol Number: NI-0501-05 | Start Date*: 2013-06-19 | |||||||||||
Sponsor Name:NovImmune SA | |||||||||||||
Full Title: A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody. | |||||||||||||
Medical condition: haemophagocytic lymphohistiocytosis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) CZ (Completed) DE (Completed) ES (Completed) AT (Completed) SE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022248-19 | Sponsor Protocol Number: 114825 | Start Date*: 2011-01-25 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination ... | |||||||||||||
Medical condition: Evaluation of persistence of immune responses following immunisation of healthy elderly subjects (60-69 and ≥70 years) against Herpes Zoster (HZ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) NL (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001167-93 | Sponsor Protocol Number: Sobi.IMMUNO-101 | Start Date*: 2020-03-27 | |||||||||||
Sponsor Name:SWEDISH ORPHAN BIOVITRUM AB (PUBL) | |||||||||||||
Full Title: A phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFN¿... | |||||||||||||
Medical condition: SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001030-29 | Sponsor Protocol Number: V212-014 | Start Date*: 2014-05-27 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||
Full Title: A Phase III, Double-blind, Lot-to-Lot Consistency Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults | ||
Medical condition: Prevention of herpes zoster in adults with autoimmune disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-004268-31 | Sponsor Protocol Number: 20110118 | Start Date*: 2011-12-13 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Adalimumab (Humira) in the treatment of chronic pouchitis | |||||||||||||
Medical condition: Chronic pouchitis after proctocolectomy and reconstruction with a J-pouch and with ulcerative colitis as primary diagnosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
